Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS

K. L. Ferrante, J. Shefner, H. Zhang, R. Betensky, M. O'Brien, H. Yu, M. Fantasia, J. Taft, M. F. Beal, B. Traynor, K. Newhall, P. Donofrio, J. Caress, C. Ashburn, B. Freiberg, C. O'Neill, C. Paladenech, T. Walker, A. Pestronk, B. AbramsJ. Florence, R. Renna, J. Schierbecker, B. Malkus, M. Cudkowicz

Research output: Contribution to journalArticle

131 Scopus citations

Abstract

An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

Original languageEnglish
Pages (from-to)1834-1836
Number of pages3
JournalNeurology
Volume65
Issue number11
DOIs
StatePublished - Dec 1 2005

Fingerprint Dive into the research topics of 'Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS'. Together they form a unique fingerprint.

  • Cite this

    Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M. F., Traynor, B., Newhall, K., Donofrio, P., Caress, J., Ashburn, C., Freiberg, B., O'Neill, C., Paladenech, C., Walker, T., Pestronk, A., ... Cudkowicz, M. (2005). Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology, 65(11), 1834-1836. https://doi.org/10.1212/01.wnl.0000187070.35365.d7